The Burden of Overactive Bladder on US Public Health


Overactive bladder (OAB) is a highly prevalent symptom condition that affects millions of US men and women. Not only can the symptoms of OAB be very bothersome, but OAB can have significant detrimental effects on many aspects of individuals’ lives, representing a particularly impactful health burden to quality of life and productivity. Estimates of the individual and societal costs for the management of OAB continue to rise, particularly as effective treatments remain elusive. As such, OAB represents a significant public health burden to the USA.

This is a preview of subscription content, access via your institution.


Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.

    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78.

    Article  PubMed  Google Scholar 

  2. 2.

    Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36. doi:10.1007/s00345-002-0301-4.

    CAS  PubMed  Google Scholar 

  3. 3.

    Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–7. doi:10.1016/j.urology.2010.08.039.

    Article  PubMed  Google Scholar 

  4. 4.

    Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012;80(1):90–6. doi:10.1016/j.urology.2012.04.004.

    Article  PubMed  Google Scholar 

  5. 5.••

    Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32(3):230–7. doi:10.1002/nau.22295. The OAB-POLL study is one of the most recent population-based studies to specifically examine the impact of OAB on work productivity and physical activity.

    Article  PubMed  Google Scholar 

  6. 6.

    CDC. National Health and Nutrition Examination Study. 2015.

  7. 7.

    Dooley Y, Kenton K, Cao G, Luke A, Durazo-Arvizu R, Kramer H, et al. Urinary incontinence prevalence: results from the National Health and Nutrition Examination Survey. J Urol. 2008;179(2):656–61. doi:10.1016/j.juro.2007.09.081.

    Article  PubMed  Google Scholar 

  8. 8.

    Hartmann K, McPheeters M, Biller D, Ward R, McKoy J, Jerome R, et al. Treatment of overactive bladder in women. Evidence report/technology assessment No. 187. Rockville, MD: Agency for Healthcare Research and Quality; 2009.

    Google Scholar 

  9. 9.

    Coyne KS, Margolis MK, Kopp ZS, Kaplan SA. Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study. Urology. 2012;79(1):95–101. doi:10.1016/j.urology.2011.09.010.

    Article  PubMed  Google Scholar 

  10. 10.

    Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013;67(10):1015–33. doi:10.1111/ijcp.12164.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin. 2007;23(1):65–76. doi:10.1185/030079907X159533.

    Article  PubMed  Google Scholar 

  12. 12.

    Kinsey D, Pretorius S, Glover L, Alexander T. The psychological impact of overactive bladder: a systematic review. J Health Psychol. 2014. doi:10.1177/1359105314522084.

    PubMed  Google Scholar 

  13. 13.

    Vrijens D, Drossaerts J, van Koeveringe G, Van Kerrebroeck P, van Os J, Leue C. Affective symptoms and the overactive bladder—a systematic review. J Psychosom Res. 2015;78(2):95–108. doi:10.1016/j.jpsychores.2014.11.019.

    Article  PubMed  Google Scholar 

  14. 14.

    Coyne KS, Sexton CC, Clemens JQ, Thompson CL, Chen CI, Bavendam T, et al. The impact of OAB on physical activity in the United States: results from OAB-POLL. Urology. 2013;82(4):799–806. doi:10.1016/j.urology.2013.05.035.

    Article  PubMed  Google Scholar 

  15. 15.

    Coyne KS, Sexton CC, Thompson CL, Clemens JQ, Chen CI, Bavendam T, et al. Impact of overactive bladder on work productivity. Urology. 2012;80(1):97–103. doi:10.1016/j.urology.2012.03.039.

    Article  PubMed  Google Scholar 

  16. 16.

    Tang DH, Colayco DC, Khalaf KM, Piercy J, Patel V, Globe D, et al. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder. BJU Int. 2014;113(3):484–91. doi:10.1111/bju.12505.

    Article  PubMed  Google Scholar 

  17. 17.

    Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D. Employees with overactive bladder: work loss burden. J Occup Environ Med / Am Coll Occup Environ Med. 2005;47(5):439–46.

    Article  Google Scholar 

  18. 18.

    McKinlay JB, Link CL. Measuring the urologic iceberg: design and implementation of the Boston Area Community Health (BACH) Survey. Eur Urol. 2007;52(2):389–96. doi:10.1016/j.eururo.2007.03.013.

    Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Irwin DE, Milsom I, Kopp Z, Abrams P. Symptom bother and health care-seeking behavior among individuals with overactive bladder. Eur Urol. 2008;53(5):1029–37. doi:10.1016/j.eururo.2008.01.027.

    Article  PubMed  Google Scholar 

  20. 20.

    Reynolds WS, McPheeters M, Blume J, Surawicz T, Worley K, Wang L, et al. Comparative effectiveness of anticholinergic therapy for overactive bladder in women: a systematic review and meta-analysis. Obstet Gynecol. 2015;125(6):1423–32. doi:10.1097/AOG.0000000000000851.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Shamliyan T, Wyman JF, Ramakrishnan R, Sainfort F, Kane RL. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review. Ann Intern Med. 2012;156(12):861–74. doi:10.7326/0003-4819-156-12-201206190-00436. W301-10.

    Article  PubMed  Google Scholar 

  22. 22.

    Chancellor MB, Migliaccio-Walle K, Bramley TJ, Chaudhari SL, Corbell C, Globe D. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther. 2013;35(11):1744–51. doi:10.1016/j.clinthera.2013.08.017.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract. 2011;65(5):567–85. doi:10.1111/j.1742-1241.2010.02626.x.

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Hall SA, Link CL, Hu JC, Eggers PW, McKinlay JB. Drug treatment of urological symptoms: estimating the magnitude of unmet need in a community-based sample. BJU Int. 2009;104(11):1680–8. doi:10.1111/j.1464-410X.2009.08686.x.

    Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Maserejian NN, Minassian VA, Chen S, Hall SA, McKinlay JB, Tennstedt SL. Treatment status and risk factors for incidence and persistence of urinary incontinence in women. Int Urogynecol J. 2014;25(6):775–82. doi:10.1007/s00192-013-2288-3.

    Article  PubMed  Google Scholar 

  26. 26.

    Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–82. doi:10.1111/j.1464-410X.2009.09036.x.

    Article  PubMed  Google Scholar 

  27. 27.

    Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–63. doi:10.1016/j.juro.2012.09.079.

    Article  PubMed  Google Scholar 

  28. 28.••

    Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological A. Society of Urodynamics FPM. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80. doi:10.1016/j.juro.2015.01.087. The AUA/SUFU Guidelines provide the most up-to-date, evidence-based guidelines for the diagnosis and treatment of OAB.

    Article  PubMed  Google Scholar 

  29. 29.

    Ju R, Garrett J, Wu JM. Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States. Int Urogynecol J. 2013. doi:10.1007/s00192-013-2246-0.

    PubMed  Google Scholar 

  30. 30.

    Subak L, Van Den Eeden S, Thom D, Creasman JM, Brown JS. Reproductive Risks for Incontinence Study at Kaiser Research G. Urinary incontinence in women: direct costs of routine care. Am J Obstet Gynecol. 2007;197(6):596. doi:10.1016/j.ajog.2007.04.029. e1-9.

    Article  PubMed  Google Scholar 

  31. 31.

    Subak LL, Brown JS, Kraus SR, Brubaker L, Lin F, Richter HE, et al. The “costs” of qurinary incontinence for women. Obstet Gynecol. 2006;107(4):908–16. doi:10.1097/01.AOG.0000206213.48334.09.

    Article  PubMed  PubMed Central  Google Scholar 

  32. 32.••

    Ganz ML, Smalarz AM, Krupski TL, Anger JT, Hu JC, Wittrup-Jensen KU, et al. Economic costs of overactive bladder in the United States. Urology. 2010;75(3):526–32. doi:10.1016/j.urology.2009.06.096. The authors use prevalence-based models and a variety of current published sources to calculate the most comprehensive estimate for the total US societal costs for OAB.

    Article  PubMed  Google Scholar 

  33. 33.

    Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD. The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care. 2009;15(4 Suppl):S90–7.

    PubMed  Google Scholar 

  34. 34.

    Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004;63(3):461–5. doi:10.1016/j.urology.2003.10.037.

    Article  PubMed  Google Scholar 

  35. 35.

    Hu TW, Wagner TH, Bentkover JD, LeBlanc K, Piancentini A, Stewart WF, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61(6):1123–8.

    Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to W. Stuart Reynolds.

Ethics declarations

Conflict of Interest

Dr. Reynolds and Dr. Fowke declare that they have no conflict of interest. Dr. Dmochowski reports personal fees from Allergan and personal fees from Medtronic, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Overactive Bladder

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Reynolds, W.S., Fowke, J. & Dmochowski, R. The Burden of Overactive Bladder on US Public Health. Curr Bladder Dysfunct Rep 11, 8–13 (2016).

Download citation


  • Overactive bladder
  • Public health
  • Epidemiology
  • Health economics